Clinical trials: At Risk for HIV
HIV Preexposure Prophylaxis
Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)
The main purpose of the study is to evaluate the safety and tolerability of oral Islatravir (ISL) once monthly (QM) as Preexposure Prophylaxis (PrEP) in cisgender men who have sex with men (MSM) and transgender women (TGW) who…
- Trial name
- Impower-024 (NCT04652700)
- Testing
- ISL, FTC/TDF, FTC/TAF
- Where
- 25 sites in United States, Brazil and 5 more
- Volunteers
- 494 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
HIV, HIV Pre-exposure Prophylaxis
Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)
This double-blind, placebo-controlled study was designed to assess the safety, tolerability, and pharmacokinetics of oral MK-8527 taken once monthly (QM) in participants at low risk for human immunodeficiency virus Type 1 (HIV-1)…
- Trial name
- NCT06045507
- Testing
- MK-8527
- Where
- 18 sites in United States, Israel and 1 more
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Acquired Immune Deficiency Syndrome Virus, Hepatitis C
Brief Intervention for Rural Women at High Risk for HIV/HCV
The overall aim of this study is to reduce risk behaviors and increase health and behavioral health service utilization among disadvantaged, drug-using rural women at high risk for HIV and HCV.
- Conditions
- Acquired Immune Deficiency Syndrome Virus, Hepatitis C, Drug Abuse
- Trial name
- WISH (NCT01840722)
- Testing
- MI-based HIV Risk Reduction
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Michele Staton
Treatment
Brief Acceptance and Commitment Therapy for HIV-infected At-risk Drinkers
Alcohol consumption at hazardous levels is associated with negative consequences on nearly every step of the HIV care continuum.
- Trial name
- NCT03974061
- Testing
- Brief Acceptance and Commitment Therapy, Brief Alcohol Intervention
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Syracuse University
HIV
HIV Prevention Toolkit for HIV-negative Male Couples
Though technology is integrated into the lives of our target population, use of any particular technology will depend on the content delivered, aesthetic appeal, and overall design.
- Trial name
- MCAP (NCT02494817)
- Testing
- Male Couples Agreement Project
- Where
- United States
- Volunteers
- 298 people, healthy volunteers welcome
- Sponsor
- University of Miami
Pre-Exposure Prophylaxis of HIV Infection
Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth…
- Trial name
- PURPOSE 2 (NCT04925752)
- Testing
- Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN)
- Where
- 93 sites in United States, Argentina and 6 more
- Volunteers
- 3,292 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Opioid-Related Disorders
Buprenorphine Group Medical Visits in Primary Care
The primary goal of this research is to improve the effectiveness of buprenorphine maintenance treatment (BMT) within primary care.
- Trial name
- G-BMT (NCT02526212)
- Testing
- G-BMT, Treatment as usual, Buprenorphine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Montefiore Medical Center
HIV, Hepatitis B
Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests
This is a pilot, monocentric, prospective, randomized control trial looking at the use of rapid tests as a part of normal care. The investigators will be testing for hepatitis B virus (HBV), hepatitis C virus (HCV), and human…
- Conditions
- HIV, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular
- Trial name
- OPTISCREEN-III (NCT01790633)
- Testing
- ELISA, Rapid Test
- Where
- France
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Endothelial Dysfunction
A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease
This research study is to see whether blood vessel function, an early sign of heart disease, improves in HIV-infected men and women who take telmisartan for 12 weeks.
- Trial name
- NCT01578772
- Testing
- Telmisartan
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Los Angeles
HIV-I, Human Immunodeficiency Virus Type 1
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
This study will evaluate whether oral islatravir (ISL) is effective in preventing Human Immunodeficiency Virus Type 1 (HIV-1) infection in women at high-risk for HIV-1 infection.
- Conditions
- HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis
- Trial name
- Impower-022 (NCT04644029)
- Testing
- Islatravir, FTC/TDF
- Where
- 24 sites in United States, South Africa and 1 more
- Volunteers
- 730 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV-infection/AIDS
WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)
The objective of this application is to increase PrEP uptake among women vulnerable to HIV acquisition in the rural South, specifically those seeking care at Federally Qualified Healthcare Centers (FQHC) in rural Alabama.
- Trial name
- PrEP (NCT04373551)
- Testing
- Cultural adaptation of a patient-provider communication tool
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of Alabama at Birmingham
HIV
Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women
This study seeks to understand the immune cells in the cervical fluid of in the blood and genital tract of HIV-negative healthy female volunteers and to see if these cells can be modified using a combined anti-viral and…
- Trial name
- MIP (NCT02333045)
- Testing
- Truvada qd, Maraviroc 300 qd
- Where
- 2 sites in United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Emory University
HIV-1 Infection
Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
This study will evaluate the safety, tolerability and pharmacokinetics (PK) of 6 once-monthly doses of oral islatravir (60 mg and 120 mg) compared with placebo in adults at low risk of HIV-1 infection
- Trial name
- NCT04003103
- Testing
- Islatravir
- Where
- 9 sites in United States, Israel and 1 more
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV, HIV Testing
A Reinforcement Intervention for Increasing HIV Testing Among At-Risk Women
African American and Latina women, as well as women living in poverty, are an identified health disparities population for HIV. Risks for HIV are compounded in this population when additional risk factors are present, including…
- Conditions
- HIV, HIV Testing, Women, Contingency Management
- Trial name
- NCT03768986
- Testing
- Standard referral for HIV testing, Online risk reduction training, Reinforcement
- Where
- United States
- Volunteers
- 364 people
- Sponsor
- UConn Health
Pre-Exposure Prophylaxis of HIV Infection
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) and emtricitabine/tenofovir alafenamide (F/TAF) in preventing HIV infection, in adolescent girls and young women (AGYW).
- Trial name
- PURPOSE 1 (NCT04994509)
- Testing
- Oral Lenacapavir (LEN), Subcutaneous (SC) Lenacapavir (LEN), F/TAF
- Where
- 28 sites in South Africa, Uganda
- Volunteers
- 5,368 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Latent Tuberculosis Infection
Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV
Tuberculosis (TB) is the prototypical disease of poverty as it disproportionately affects marginalized and impoverished communities.
- Trial name
- 3HP-LTBI (NCT03702049)
- Testing
- Nurse-led Community Health Worker TBI (RN/CHW TBI) program
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, Irvine
HIV Infections, Sexually Transmitted Diseases
A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs
This study will determine the effectiveness of a peer outreach intervention in preventing HIV infection in adults at high risk for contracting HIV and other sexually transmitted diseases (STDs).
- Trial name
- NCT00183456
- Testing
- Peer-oriented intervention, Group cognitive behavioral therapy (CBT)
- Where
- United States
- Volunteers
- 746 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Pre-exposure Prophylaxis, HIV Infections
Le Kip Kip: A Campaign to Change Social Norms and Build Sustainable Demand for PrEP Among Women in South Africa
The purpose of this study is to evaluate the impact of a social media campaign and community engagement activities to promote pre-exposure prophylaxis (PrEP) use among young women and to influence community norms around PrEP in…
- Trial name
- NCT05417620
- Testing
- Social Media Campaign, PrEP Champions, Community Mobilization
- Where
- South Africa
- Volunteers
- 601 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Alcohol; Harmful Use, Binge Drinking
Computerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women
African American (AA) women are disproportionately affected by HIV/AIDs. The major risk factor for HIV acquisition among AA women is high-risk heterosexual sex, including unprotected vaginal and anal sex, and sex with a high-risk…
- Conditions
- Alcohol; Harmful Use, Binge Drinking, Risk Behavior, HIV Infection
- Trial name
- NCT01125371
- Testing
- Computerized brief alcohol intervention + IVR booster calls, Computerized brief alcohol intervention, Attention Control
- Where
- United States
- Volunteers
- 439 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University